Dr Agarwals Eye Hospital Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Dr Agarwals Eye Hospital Ltd trades at ₹4,995, in a confirmed uptrend and 11 weeks into that stage. That is +1.4% against its own 200-day average. It sits at 44% of a 52-week range of ₹4,405 to ₹5,735. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (5 weeks and counting).

Today the stock is in a confirmed uptrend — week 11 of stage 2, confirmed. At ₹4,995 it trades +1.4% versus its 200-day average and sits at 44% of its 52-week range (₹4,405–₹5,735).

Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +2,571% while the NIFTY 500 moved +276% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (5 weeks and counting; last ahead the week of 2026-07-01) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Dr Agarwals Eye Hospital Ltd trades at 34.6× P/E, at the pricey end of its own range (70th percentile). Its long-run median P/E is 28.6×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 34.6× is at the pricey end of its own range (70th percentile), against a long-run median of 28.6× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved +24.7% against a +12.8% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 5y, of the +64.0%/yr price move, ~+65.9%/yr came from earnings growth and ~−1.9 pp from the multiple (compressing); over 10y, of the +38.5%/yr price move, ~+41.9%/yr came from earnings growth and ~−3.4 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Dr Agarwals Eye Hospital Ltd reads as consistent on its fundamental arc. Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 17.8% and holding. The read is built from 12 quarters across 4 curves, on full evidence.

Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.

4-Factor Sector Score

54.3/100 — rank 8 of 19 in Hospitals · 90% evidence confidence

Dr Agarwals Eye Hospital Ltd scores 54.3 out of 100 against the 19 companies it is compared with in Hospitals, ranking 8. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 19.6 + 16.8 + 10.6 + 7.3 = 54.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Dr Agarwals Eye Hospital Ltd reported ₹120 Cr of revenue in the Mar 26 quarter, +20.0% year on year. That is the 12th straight quarter of year-on-year growth. Over 10 years it has compounded at 13.1% a year. The last full year, FY26, came in at ₹471 Cr. The last four reported quarters add to ₹471 Cr.

FY26 revenue came in at ₹471 Cr (+18.6% on the year), capping 10 years at 13.1% compound. The latest quarter (Mar 26) printed ₹120 Cr, +20.0% year on year — the 12th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +18.7% growth against the decade's 13.1% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +18.6% over the last 4 quarters against +21.3%/yr over the last 8 — stabilising; TTM profit +27.8% vs +21.2%/yr — accelerating.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Dr Agarwals Eye Hospital Ltd's operating margin is 28.0% in the Mar 26 quarter, −4.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 13 fiscal years the operating margin has ranged 9.0% to 31.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 28.0%, −4.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 9.0%–31.0%, and FY26's 31.0% is the top of that band — a record year.

🚨 Why the margin moved: operating margin went −3.5 pp year on year while gross margin went +1.4 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Dr Agarwals Eye Hospital Ltd earned ₹16.0 Cr of net profit in the Mar 26 quarter, +0.0% year on year. Full-year FY26 profit was ₹70.0 Cr. That is 13.3% of the quarter's revenue. The same quarter a year earlier earned ₹16.0 Cr.

Mar 26 profit was ₹16.0 Cr, +0.0% year on year. On the full year, FY26 printed ₹70.0 Cr (+27.3%).

🚨 Why profit moved: revenue contributed +20.0% and the margin −4.0 pp — the quarter was revenue-led despite a thinner margin.

Pace comparison, last four quarters: profit +31.8% vs revenue +18.7%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 192% of Dr Agarwals Eye Hospital Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹145 Cr of operating cash against ₹70.0 Cr of profit. After ₹125 Cr of capital spending, ₹20.0 Cr was left as free cash.

FY26: operating cash of ₹145 Cr against reported profit of ₹70.0 Cr, leaving free cash of ₹20.0 Cr after ₹125 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 192% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 192%: the cash cycle stretched 176 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.

Router verdict: the bigger cash user is investment — capital spending ran 3.5× depreciation over three years, so the next section's job is to check what that build-out is buying.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Dr Agarwals Eye Hospital Ltd's cash conversion cycle runs −84 days in FY26, up from −260 days in FY21. Capital spending ran ₹390 Cr over the last 3 years. At FY26 sales of ₹471 Cr each day of that cycle holds about ₹1.3 Cr, so roughly ₹−108 Cr sits inside the business at any moment.

FY26: debtors at 14 days, inventory at 109 days — roughly 3.6 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −84 days, looser than FY21's −260.

The full loop: cash goes out to suppliers and production on day 0; stock waits 109 days to sell; customers pay about 14 days after that; and suppliers themselves are paid at 208 days — netting out to the −84-day cycle.

In money terms: at FY26 sales of ₹471 Cr, each day of the cycle holds about ₹1.3 Cr — so the −84-day loop keeps roughly ₹−108 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹390 Cr over the last 3 fiscal years against ₹112 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹197 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Dr Agarwals Eye Hospital Ltd earns a ROCE of 17% in FY26. That is up from a trough of 11% in FY21. Return on invested capital clears the cost of that capital by +1.8 percentage points, so growth here adds value rather than only size. The wiring behind it is 14.9% net margin on 0.61× asset turns.

FY26 ROCE is 17%, recovered from a FY21 trough of 11% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): 14.9% net margin × 0.61× asset turns × 2.21× balance-sheet leverage ≈ 20.1% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 13.8% − 12.0% = a +1.8 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Dr Agarwals Eye Hospital Ltd carries total debt of ₹326 Cr against shareholder equity of ₹346 Cr as of Mar 26, a debt-to-equity of 0.94. On the annual view that ratio went from 2.47 in FY22 to 0.94 in FY26. Read the returns elsewhere on this page with that leverage in mind.

Mar 26: total debt of ₹326 Cr against shareholder equity of ₹346 Cr — a debt-to-equity of 0.94. On the annual view, debt-to-equity went from 2.47 (FY22) to 0.94 (FY26). Read the returns on this page with that leverage in mind.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Domestic institutions added 2.0 points of Dr Agarwals Eye Hospital Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 2.0% of the company. Foreign institutions moved +1.6 points over the same window, to 2.2%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Domestic institutions: +2.0 points over 8 quarters to 2.0%; Foreign institutions: +1.6 points over 8 quarters to 2.2%; Promoters: +0.8 points over 8 quarters to 72.7%.

Why the register moved: domestic institutions drove it (+2.0 points), alongside foreign institutions (+1.6 points) — steady accumulation by institutions reading the same numbers this page reads.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Dr Agarwals Eye Hospital Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions